Gary Schoolnik News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea, Neisseria gonorrhoeae (NG), and its susceptibility to ciprofloxacin, a former frontline oral antibiotic that can no longer treat resistant NG.

Vector-borne illnesses have doubled over the past two decades, as the number of pathogens grows and affected areas expand.

Sporadic infections will likely continue, especially in areas where H5N1 is still endemic in poultry.

CWD prions (misfolded proteins) were found in a county scrape, or area that bucks defoliate by pawing, in June.

The portable test from Visby Medical will be able to detect gonorrhea and assess susceptibility to ciprofloxacin.